Diagnosis
Breakthrough AI solution to advance early detection in women’s health

Covera Health has announced the launch of Protect Her – an AI-powered solution designed to enhance early detection of critical health conditions predominantly impacting women ages 40 and up.
Protect Her utilises latest advances in radiology AI to identify early signs of breast cancer, cardiovascular disease and osteoporosis during routine scans that women are already receiving, such as mammograms, chest CTs, and chest x-rays.
Covera Health says the platform can often detect disease before symptoms appear, enabling women to proactively seek timely, and potentially lifesaving care.
“Early detection is the single most powerful tool we have to improve health outcomes, particularly for women, who are frequently underdiagnosed in these areas,” said Ron Vianu, CEO of Covera Health.
“Protect Her empowers providers with AI-powered insights that can detect serious and life-threatening conditions early, allowing women to get the right care before it’s too late. This is a game-changer for women’s health.”
Protect Her works by analysing imaging studies that women are already undergoing to flag undetected conditions that traditional radiology may overlook such as breast cancer, cardiovascular disease, and osteoporosis.
“AI has the ability to transform how we practice medicine, especially when it comes to our ability to detect early signs of disease,” said Dr. Phoebe Freer, a professor of radiology and breast cancer screening leader with the American College of Radiology.
“By using advanced technology to analyse a patient’s image beyond the primary concern, we can detect high-impact conditions more readily, giving patients and their physicians critical insights that may help them act before a crisis occurs.”
Pregnancy
Home blood pressure checks could lower heart risks for new mothers – study
Diagnosis
Researchers teach AI to spot cancer risk by squeezing individual breast cells
Diagnosis
Experimental drug drowns triple-negative breast cancer cells in toxic fats

An experimental drug slowed triple-negative breast cancer in mice by flooding tumour cells with toxic fats.
Triple-negative breast cancer lacks three common drug targets, making it one of the hardest-to-treat and most aggressive forms of the disease.
The compound, known as DH20931, appears to push cancer cells past their limits by triggering a surge in ceramides, fat-like molecules that place the cells under intense stress until they self-destruct.
In lab experiments, the drug also made standard chemotherapy more effective. When combined with doxorubicin, researchers were able to reduce the dose needed to kill cancer cells by about fivefold.
The drug targets an enzyme known as CerS2 to sharply increase production of these lipids and stress cancer cells. Healthy cells, by contrast, showed lower sensitivity to the drug in lab tests.
While the early results are promising, further preclinical and clinical trials would still be needed to determine the safety and effectiveness of DH20931 in humans.
Satya Narayan, a professor in the University of Florida’s College of Medicine, led the study with an international group of collaborators.
The researchers published their results on human-derived tumours on 21 April and presented their findings on combination therapy at the annual meeting of the American Association for Cancer Research in San Diego.
Narayan likened the drug’s effects to a home’s electrical system handling a power surge.
While healthy cells act like a properly grounded and installed circuit, cancer cells are more like a jumble of mismatched wires and faulty fuses. DH20931 overwhelms cells not with electricity, but with fats.
He said: “When that surge goes into the cancer cells, they cannot handle the amount of power they are getting. The fuses burn out, the cell can’t handle the surge and it dies.”
The compound was developed at the University of Florida in the lab of Sukwong Hong.
Hong, now a professor at the Gwangju Institute of Science and Technology in South Korea, created DH20931 as one of many drug candidates tested for efficacy in Narayan’s lab.
In the study, researchers implanted human triple-negative breast cancer tumours into mice and treated them with DH20931.
The drug significantly slowed tumour growth without causing noticeable weight loss or signs of toxicity in the animals. In separate lab experiments, it also showed activity against other breast cancer subtypes.
In addition to increasing lipid levels, DH20931 triggers a second stress signal by flooding cells with calcium.
Together, these effects disrupt the mitochondria, the structures that produce a cell’s energy, ultimately leading to cell death.
Narayan said: “It does not just follow one pathway but it goes through multiple pathways. It’s a two-hit hypothesis.
“These pathways are common in all breast cancer types and other solid tumours, so we think this drug can be useful not only in triple-negative breast cancer but potentially other cancers as well.”
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Fertility4 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion4 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Mental health6 days agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says















